Vitamin D Receptor: No Evidence for Allele-Specific mRNA Stability in Cells Which Are Heterozygous for the Taq I Restriction Enzyme Polymorphism

doi:10.1006/bbrc.1997.7239

Biochemical and Biophysical Research Communications

Volume 238, Issue 1, 8 September 1997, Pages 77-80

https://doi.org/10.1006/bbrc.1997.7239 Get rights and content

Abstract

Allelic variations of the vitamin D receptor (VDR) gene have been associated with the risk of developing prostate cancer in men and osteoporosis in postmenopausal women. Three RFLP's (TaqI, ApaI, BsmI) define two common haplotypes: BAt and baT. None of these polymorphisms change the translated protein. Since sequence variations in the 3′ UTR of VDR have been linked to the different haplotypes, investigators have proposed that the stability of VDR mRNA is influenced by allelic variations. Indirect evidence suggested that allele T is less stable than allele t. In this study, we used a RT-PCR based approach to compare the stability of the big T and small t allele in normal heterozygous lymphocytes and the heterozygous cell lines NB4 (myeloid leukemia) and PC-3 and DU 145 (prostate cancers). In all three cases, we did not find a significant difference in stability. Interestingly, we consistently observed 30% less RT-PCR product derived from the small t allele mRNA in steady state, a finding which also speaks against a higher stability of the small t allele mRNA. These results indicate a variation in transcriptional regulation rather than mRNA stability between the alleles. We hypothesize that an unknown gene or genes in linkage with the polymorphisms is (are) responsible for the relationship between risk of prostate cancer and VDR polymorphisms.

References (22)

S. Farrow
Lancet
(1994)
T.E. Hedlund et al.
J Steroid Biochem and Mol Biol
(1996)
A.B. Sachs
Cell
(1993)
A. Mahonen et al.
Biochem Biophys. Res Comm.
(1994)
J.A. Taylor et al.
Cancer Res.
(1996)
S.A. Ingles et al.
J. Natl. Cancer Institute
(1997)
N.A. Morrison et al.
Nature
(1994)
J.A. Eismann
J. of Bone and Mineral Res.
(1995)
M. Peacock
Journal of Bone and Mineral Research
(1995)
P. Garnero et al.
J. of Bone and Mineral Res.
(1995)

There are more references available in the full text version of this article.

Cited by (96)

Significant Association of Poly-A and Fok1 Polymorphic Alleles of the Vitamin D Receptor with Vitamin D Serum Levels and Incidence of Squamous Cutaneous Neoplasia
2023, Journal of Investigative Dermatology
Vitamin D3, a prohormone, is converted to circulating calcidiol and then to calcitriol, the hormone that binds to the vitamin D receptor (VDR) (a nuclear transcription factor). Polymorphic genetic sequence variants of the VDR are associated with an increased risk of breast cancer and melanoma. However, the relationship between VDR allelic variants and the risk of squamous cell carcinoma and actinic keratosis remains unclear. We examined the associations between two VDR polymorphic sites, Fok1 and Poly-A, and serum calcidiol levels, actinic keratosis lesion incidence, and the history of cutaneous squamous cell carcinoma in 137 serially enrolled patients. By evaluating the Fok1 (F) and (f) alleles and the Poly-A long (L) and short (S) alleles together, a strong association between genotypes FFSS or FfSS and high calcidiol serum levels (50.0 ng/ml) was found; conversely, ffLL patients showed very low calcidiol levels (29.1 ng/ml). Interestingly, the FFSS and FfSS genotypes were also associated with reduced actinic keratosis incidence. For Poly-A, additive modeling showed that Poly-A (L) is a risk allele for squamous cell carcinoma, with an OR of 1.55 per copy of the L allele. We conclude that actinic keratosis and squamous cell carcinoma should be added to the list of squamous neoplasias that are differentially regulated by the VDR Poly-A allele.
Vitamin D and tuberculosis
2023, Feldman and Pike's Vitamin D: Volume Two: Disease and Therapeutics
Tuberculosis is a major global health problem: The World Health Organization estimates that there were 10.6 million incident cases and 1.6 million deaths from the disease in 2021. The development of new agents to prevent acquisition or reactivation of latent Mycobacterium tuberculosis infection and to allow shortening of antimicrobial therapy regimens for active tuberculosis without loss of efficacy is a research priority. This chapter describes the immunomodulatory actions of vitamin D metabolites in mycobacterial infection and reviews the latest evidence from observational and intervention studies investigating a potential role for vitamin D in the prevention and treatment of tuberculosis.
Immunomodulatory effects of 25-hydroxyvitamin D<inf>3</inf> on monocytic cell differentiation and influence of vitamin D<inf>3</inf> polymorphisms in type 1 diabetes
2015, Journal of Steroid Biochemistry and Molecular Biology
Citation Excerpt :
Several studies [32] reported an association of SNPs BsmI and TaqI with T1D. Even though polymorphisms of BsmI and TaqI do not lead to structural changes on the VDR, they seem to influence the function of neighboring sequences by impacting messenger-RNA stability and transcription regulation [33,34]. Gene coupling of allele b and T has been suggested by Pani et al. [35] as well.
Preventive measures and a causal therapy for type 1 diabetes (T1D) remain elusive. An imbalance between different dendritic cells (DC) with increased immunogenic DC and decreased tolerogenic DC (tDC) may lead to T1D. Furthermore, 25(OH)D₃ is associated with less adverse effects than 1,25(OH)₂D₃.
The present study was performed to clarify the remaining issues about the cellular effects of 25(OH)D₃ in patients with T1D and the role of genetic polymorphisms of the vitamin D₃ (VD₃) metabolism on a functional cellular level.
Twelve patients with T1D were case-matched to twelve healthy controls (HC). Monocytes (MC) were either not supplemented or supplemented with 25(OH)D₃ in vitro and phenotyped with fluorescence-activated cell sorting. In vitro synthesis and plasma levels of 25(OH)D₃ and 1,25(OH)₂D₃ were analyzed as well as twelve gene polymorphisms of the VD₃ metabolism.
25(OH)D₃ significantly inhibited differentiation of MC into DC and led to an increase of intermediate cells (IC), which show a similar phenotype as tDC. The patient with a recent onset of T1D showed a higher increase in MC and IC compared to patients with long-standing T1D. There were significant differences for the increase of IC with supplementation of 25(OH)D₃ between different genotypes within the polymorphisms of VDR-BsmI-rs1544410, VDR-TaqI-rs731236 and CYP24A1-rs927650.
This study suggests that 25(OH)D₃ shows immunomodulatory effects on a cellular level in patients with T1D and HC by inhibiting the differentiation of MC into DC and promoting the formation of IC, which are similar to tDC, thereby shifting immunity to self-tolerance. The potency of 25(OH)D₃ did not differ between patients with T1D and HC. Increased plasma levels of 25(OH)D₃ may inhibit a proinflammatory cell milieu. Despite of the limited patient number, this study generates the hypothesis that the immunmodulatory effects may be influenced by genotypes of the VDR and CYP24A1 illustrating their functional role in T1D susceptibility, which is worth further investigation.
Genetics of primary progressive multiple sclerosis
2014, Handbook of Clinical Neurology
Citation Excerpt :
A Taq1 RFLP in the ninth exon of the VDR gene was more overrepresented in MS patients relative to controls (OR = 2.35, p = 0.0069). This polymorphism alters gene transcription but does not result in an amino acid substitution (Verbeek et al., 1997). This study also claims that the VDR Taq1 polymorphism is more prevalent in SPMS and PPMS patients than in RRMS patients, although the confidence intervals surrounding the point estimates of the ORs in these subgroups overlap.
Multiple sclerosis (MS) patients are classified as either having relapsing onset or progressive onset disease, also known as primary progressive MS (PPMS). Relative to relapsing onset patients, PPMS patients are older at disease onset, are equally likely to be men or women, and have more rapid accumulation of disability that does not respond well to treatments used in relapsing onset MS. Although estimates vary, 5–15% of all MS patients have a PPMS disease course. Genetic variance is a proposed determinant of MS disease course. If distinct genes associated with PPMS were identified study of these genes might lead to an understanding of the biology underlying disease progression and neural degeneration that are the hallmarks of PPMS. These genes and their biological pathways might also represent therapeutic targets. This chapter systematically reviews the PPMS genetic literature. Despite the intuitively appealing notion that differences between PPMS and relapsing onset MS are due to genetics, definite differences associated with these phenotypes at the major histocompatibility complex or elsewhere in the genome have not been found. Recent large-scale genome wide screens identified multiple genes associated with MS susceptibility outside the MHC. The genetic variants identified thus far make only weak individual contributions to MS susceptibility. If the genetic effects that contribute to the differences between PPMS and relapsing MS are similar in magnitude to those that distinguish MS from healthy controls then, given the relative scarcity of the PPMS phenotype, very large datasets will be needed to identify PPMS associated genes. International collaborative efforts could provide the means to identify such genes. Alternately, it is possible that factors other than genetics underlie the differences between these clinical phenotypes.
Genetics of the Vitamin D endocrine system
2011, Vitamin D: Two-Volume Set
The secosteroid hormone vitamin D, vitamin D receptor (VDR), and the metabolizing enzymes involved in the formation of the biologically active form of the hormone, acting together, are major players in the vitamin D endocrine system. This system plays an important role in skeletal metabolism, including intestinal calcium absorption, but has also been shown to play an important role in other metabolic pathways, such as those involved in the immune response and cancer. The interpretation of polymorphic variations in candidate genes of the vitamin D endocrine system (such as the VDR gene or the DBP gene) is severely hindered by the fact that, until recently, only few polymorphisms in these genes were studied. To understand the mechanisms underlying the associations, one has to analyze the genomic organization of the loci, to identify which genes are present in the chromosomal area, to categorize all relevant polymorphisms, to determine the linked alleles (or haplotypes) across the gene, to determine their relationship with the markers used so far, and, finally, to perform association analyses with relevant phenotypic endpoints such as disease.
Genetics of the vitamin D endocrine system
2011, Vitamin D
The secosteroid hormone vitamin D, vitamin D receptor (VDR), and the metabolizing enzymes involved in the formation of the biologically active form of the hormone, acting together, are major players in the vitamin D endocrine system. This system plays an important role in skeletal metabolism, including intestinal calcium absorption, but has also been shown to play an important role in other metabolic pathways, such as those involved in the immune response and cancer. The interpretation of polymorphic variations in candidate genes of the vitamin D endocrine system (such as the VDR gene or the DBP gene) is severely hindered by the fact that, until recently, only few polymorphisms in these genes were studied. To understand the mechanisms underlying the associations, one has to analyze the genomic organization of the loci, to identify which genes are present in the chromosomal area, to categorize all relevant polymorphisms, to determine the linked alleles (or haplotypes) across the gene, to determine their relationship with the markers used so far, and, finally, to perform association analyses with relevant phenotypic endpoints such as disease.

View all citing articles on Scopus

View full text

Regular ArticleVitamin D Receptor: No Evidence for Allele-Specific mRNA Stability in Cells Which Are Heterozygous for the Taq I Restriction Enzyme Polymorphism

Abstract

Lancet

J Steroid Biochem and Mol Biol

Cell

Biochem Biophys. Res Comm.

Cancer Res.

J. Natl. Cancer Institute

Nature

J. of Bone and Mineral Res.

Journal of Bone and Mineral Research

J. of Bone and Mineral Res.

Regular Article
Vitamin D Receptor: No Evidence for Allele-Specific mRNA Stability in Cells Which Are Heterozygous for the Taq I Restriction Enzyme Polymorphism